CTOT-43
Brief description of study
This is a multicenter 2:1 randomized nonblinded phase II interventional clinical trial in liver transplant recipients to determine the safety, efficacy, and tolerability of tacrolimus minimization and eventual withdrawal in conjunction with conversion to everolimus monotherapy to preserve renal function.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
